Dual Trigger, Urinary HCG or Recombinant HCG, Which is the Best !?
NCT ID: NCT04265495
Last Updated: 2021-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
600 participants
OBSERVATIONAL
2020-02-09
2021-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)
NCT00954265
Dual Trigger Versus Booster Dose of HCG
NCT02397642
Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders
NCT04224818
Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles
NCT04008966
The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes
NCT01979341
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DUAL TRIGGERING
PATIENTS WILL RECEIVE DUAL TRIGGERING
No interventions assigned to this group
URINARY HCG
PATIENTS WILL RECEIVE URINARY HCG
No interventions assigned to this group
RECOMBINANT HCG
PATIENTS WILL RECEIVE RECOMBINANT HCG
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* BMI \> 30 ,
* long agonist protocol
* were chromosomal and genetic disorders, abnormal ultrasonogram of the uterine cavity
22 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Al Baraka Fertility Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Kamal Rageh
DOCTOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Al-BARAKA FERTILITY HOSPITAL
Manama, Adliya, Bahrain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AlBarakaBH-KAMAL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.